Rafael Grochot, Hyo S. Han, Meritxell Bellet, Erika P. Hamilton, Rodrigo Sanchez-Bayona, Valentina Boni, Patricia LoRusso, Carlo Palmieri, Hendrik-Tobias Arkenau, Anne Caroline Armstrong, Marian Girgis, Neelima Vidula, Hannah van den Boomen, Joyce O'Shaughnessy. "A phase 1/2 study of EP0062 (vosilasarm), a first-in-class oral selective androgen receptor modulator (SARM), in combination with standard-of-care endocrine therapy +/- targeted therapies in patients with advanced or metastatic AR+/ER+/HER2− breast cancer.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.tps1151